caa a22 4500 378917528 CHVBK 20180305123557.0 cr unu---uuuuu 161128e20041101xx s 000 0 eng 10.1515/CCLM.2004.244 doi (NATIONALLICENCE)gruyter-10.1515/CCLM.2004.244 The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment [Elektronische Daten] [Herlinde Dumez, Gunther Guetens, Gert De Boeck, Martin S. Highley, Robert A. A. Maes, Allan T. van Oosterom, Ernst A. de Bruijn] Therapeutic drug monitoring generally focuses on the plasma compartment only. Differentiation between the total plasma concentration and the free fraction (plasma water) has been described for a number of limited drugs. Besides the plasma compartment, blood has also a cellular fraction which has by far the largest theoretical surface and volume for drug transport. It is with anti-cancer drugs that major progress has been made in the study of partition between the largest cellular blood compartment, i.e., erythrocytes, and the plasma compartment. The aim of the present review is to detail the progress made in predicting what a drug does in the body, i.e., pharmacodynamics including toxicity and plasma and/or red blood cell concentration monitoring. Furthermore, techniques generally used in anti-cancer drug monitoring are highlighted. Data for complex Bayesian statistical approaches and population kinetics studies are beyond the scope of this review, since this is generally limited to the plasma compartment only. © Walter de Gruyter Medical equipment & techniques nationallicence Medical diagnosis nationallicence Diseases & disorders nationallicence anti-cancer drugs nationallicence erythrocyte nationallicence measurement of sediment nationallicence Dumez Herlinde LabExp Oncology, KuLeuven, Leuven, Belgium aut Guetens Gunther LabExp Oncology, KuLeuven, Leuven, Belgium and Department of Chemistry, University of Antwerp, Wilrijk, Belgium aut De Boeck Gert LabExp Oncology, KuLeuven, Leuven, Belgium aut Highley Martin S. Division of Cancer Medicine, University of Dundee, Dundee, UK aut Maes Robert A. A. Department of Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands aut van Oosterom Allan T. LabExp Oncology, KuLeuven, Leuven, Belgium aut de Bruijn Ernst A. LabExp Oncology, KuLeuven, Leuven, Belgium aut Clinical Chemistry and Laboratory Medicine Walter de Gruyter 42/11(2004-11-01), 1219-1227 1434-6621 42:11<1219 2004 42 cclm https://doi.org/10.1515/CCLM.2004.244 text/html Onlinezugriff via DOI 1 research article jats NATIONALLICENCE 856 40 https://doi.org/10.1515/CCLM.2004.244 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Dumez Herlinde LabExp Oncology, KuLeuven, Leuven, Belgium aut NATIONALLICENCE 700 1- Guetens Gunther LabExp Oncology, KuLeuven, Leuven, Belgium and Department of Chemistry, University of Antwerp, Wilrijk, Belgium aut NATIONALLICENCE 700 1- De Boeck Gert LabExp Oncology, KuLeuven, Leuven, Belgium aut NATIONALLICENCE 700 1- Highley Martin S. Division of Cancer Medicine, University of Dundee, Dundee, UK aut NATIONALLICENCE 700 1- Maes Robert A. A. Department of Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands aut NATIONALLICENCE 700 1- van Oosterom Allan T. LabExp Oncology, KuLeuven, Leuven, Belgium aut NATIONALLICENCE 700 1- de Bruijn Ernst A. LabExp Oncology, KuLeuven, Leuven, Belgium aut NATIONALLICENCE 773 0- Clinical Chemistry and Laboratory Medicine Walter de Gruyter 42/11(2004-11-01), 1219-1227 1434-6621 42:11<1219 2004 42 cclm CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-gruyter